Sinclair Pharma (XPAR:SPH) Debt-to-EBITDA : -1.37 (As of Jun. 2018)

Sinclair Pharma Debt-to-EBITDA Chart

Sinclair Pharma Annual Data
	Trend	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15	Dec17
Debt-to-EBITDA		Get a 7-Day Free Trial					-8,120.00	-1.09	9.15	-10.16	1.60

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-0.42	0.41	-1.37

Competitive Comparison of Sinclair Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Sinclair Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinclair Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sinclair Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sinclair Pharma's Debt-to-EBITDA falls into.

Sinclair Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sinclair Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2017 is calculated as

Sinclair Pharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2018) EBITDA data.

Sinclair Pharma  (XPAR:SPH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sinclair Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma (XPAR:SPH) Business Description